TickerGuard
Buy Day today: Neutral (45) Mixed market breadth · no major macro event
HCM

HUTCHMED DRC

Healthcare · Drug Manufacturers - Specialty & Generic

14.40$ -2.2% vs. previous close Closing price · As of: Nov 17, 2026

Ownership

Ownership Structure

Who owns HUTCHMED DRC (HCM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 60.8% of the shares are freely tradable; institutional investors hold 2.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 2.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.01%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 60.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 0.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 174Mio.

Largest Shareholders

Institutions

Institutions HCM
Name Stake (%) Shares Change (%) Date
Schroder Investment Management Group 0.85 1,477,494 +0.0 06/30/2026
Allianz Asset Management AG 0.39 674,511 -19.5 06/30/2026
State Street Corp 0.18 313,611 +2.9 06/30/2026
AIA Group Ltd 0.17 291,229 +0.0 06/30/2026
M&G PLC 0.14 242,791 -5.0 06/30/2026
Amundi 0.12 204,385 -12.0 06/30/2026
Jane Street Group LLC 0.11 194,472 +154.2 06/30/2026
Renaissance Technologies Corp 0.07 130,200 -1.4 06/30/2026
BNP Paribas Arbitrage, SA 0.06 104,425 -2.0 06/30/2026

Funds

Funds HCM
Name Stake (%) Shares Change (%) Date
M&G Global Emerging Markets GBP I Acc 0.11 182,462 -2.6 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?